Prodromal bullous pemphigoid
| Autor: | Jau Shyong Deng, Philina M Lamb, Michael D. Tharp, Roy A. Frye, Edward Abell |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Pemphigoid medicine.medical_specialty Dermatology Disease Prodrome Cohort Studies Pemphigoid Bullous polycyclic compounds Medicine Humans Glucocorticoids Aged Retrospective Studies Autoimmune disease business.industry Low dose Retrospective cohort study Complement C3 biochemical phenomena metabolism and nutrition Middle Aged Tetracycline medicine.disease Anti-Bacterial Agents Fluorescent Antibody Technique Direct Doxycycline Immunoglobulin G Bullous pemphigoid business Immunosuppressive Agents Cohort study |
| Zdroj: | International journal of dermatology. 45(3) |
| ISSN: | 0011-9059 |
| Popis: | Background Prodromal bullous pemphigoid (PBP) can be difficult to diagnose. Early recognition in its early stages may decrease the morbidity and progression of the disease. Clinical presentations and current treatments available for PBP will be described. Methods A retrospective review was performed on 53 patients diagnosed with PBP. Results Overall, the average disease duration of PBP was 11.8 months. The average age of presentation of PBP was 70.8 years. The most common presentations were urticaria-like plaques (67.9%), eczema-like lesions (11.3%), and dermatitis herpetiformis-like lesions (9.4%). The majority of patients responded well to low doses of systemic corticosteroids, tetracycline, and/or high potency topical corticosteroids. Conclusions Patients with PBP tend to be in their sixth or early seventh decade of life and, on average, the duration of disease is 1 year. The most common presentation of disease is urticaria-like plaques. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text